{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:58:37Z","timestamp":1781013517801,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ejim.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T22:51:15Z","timestamp":1369954275000},"page":"707-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pulmonary involvement in Fabry disease: Overview and perspectives"],"prefix":"10.1016","volume":"24","author":[{"given":"Daniel","family":"Franzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"Krayenbuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-David","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.05.003_bb0005","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Lysosomal storage disease 3. Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF01825509","article-title":"Zur Klinik und Aetiologie des Angiokeratoma","volume":"123","author":"Fabry","year":"1916","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0015","first-page":"339","article-title":"Weiterer Beitrag zur Klinik des Angiokeratoma Naeviforme (Naevus angiokeratosus)","volume":"90","author":"Fabry","year":"1930","journal-title":"Dermatol Wochenschr"},{"key":"10.1016\/j.ejim.2013.05.003_bb0020","series-title":"The metabolic basis of inherited diseases","article-title":"Glycolipid lipidosis: Fabry's disease","author":"Sweeley","year":"1966"},{"key":"10.1016\/j.ejim.2013.05.003_bb0025","first-page":"681","article-title":"Fabry's disease: a correlative clinical, morphologic and biochemical study","volume":"18","author":"Bagdade","year":"1968","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejim.2013.05.003_bb0030","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0002-9343(80)90224-7","article-title":"Chronic airflow obstruction in Fabry's disease","volume":"68","author":"Line","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2559.1991.tb01510.x","article-title":"Pulmonary vasculature in Fabry's disease","volume":"19","author":"Smith","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.ejim.2013.05.003_bb0040","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1007\/s10545-008-0930-x","article-title":"Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage","volume":"31","author":"Abe","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/thorax.55.8.720","article-title":"Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease","volume":"55","author":"Kelly","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.ejim.2013.05.003_bb0050","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0002-9343(72)90194-5","article-title":"Pulmonary involvement in Fabry's disease: a reappraisal follow-up of a San Diego kindred and review of literature","volume":"53","author":"Bartimmo","year":"1972","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2143\/AC.65.2.2047052","article-title":"Cardiopulmonary involvement in Fabry's disease","volume":"65","author":"Koskenvuo","year":"2010","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajmg.a.31600","article-title":"Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy","volume":"143","author":"Kim","year":"2007","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ejim.2013.05.003_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9343(78)90542-9","article-title":"Pulmonary involvement in Fabry's disease","volume":"64","author":"Kariman","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0075","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","article-title":"Pulmonary involvement in Fabry disease","volume":"155","author":"Brown","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000087675","article-title":"Cardiopulmonary exercise testing in Fabry disease","volume":"72","author":"Bierer","year":"2005","journal-title":"Respiration"},{"key":"10.1016\/j.ejim.2013.05.003_bb0085","first-page":"105","article-title":"Spirometric abnormalities in patients with Fabry disease and effect of enzyme replacement therapy","volume":"447","author":"Barbey","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.ejim.2013.05.003_bb0090","series-title":"Fabry disease: perspectives from 5years of FOS","article-title":"Pulmonary involvement in Fabry disease","author":"Aubert","year":"2006"},{"key":"10.1016\/j.ejim.2013.05.003_bb0095","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10545-007-0616-9","article-title":"Natural history of the respiratory involvement in Anderson-Fabry disease","volume":"30","author":"Magage","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0105","series-title":"Handbook of physiology. The respiratory system. Mechanics of breathing. Section 3, Vol. III, part 2","first-page":"659","article-title":"Lung mechanics in disease","author":"Pride","year":"1986"},{"key":"10.1016\/j.ejim.2013.05.003_bb0110","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1164\/ajrccm\/144.5.1202","article-title":"Lung function testing: Selection of reference values and interpretative strategies","volume":"144","author":"American Thoracic Society","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0120","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1183\/09031936.03.00075102","article-title":"Population impact of different definition of airway obstruction","volume":"22","author":"Celli","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1183\/09031936.00004110","article-title":"Prevalence of airflow obstruction in smokers and never-smokers in Switzerland","volume":"36","author":"Bridevaux","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0140","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.rmed.2011.01.008","article-title":"Lower limit of normal or FEV1\/FVC<0.70 in diagnosing COPD: an evidence-based review","volume":"105","author":"Mohamed Hoesein","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0150","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1741-7015-8-84","article-title":"Systematic review of the evidence relating FEV1 decline to giving up smoking","volume":"8","author":"Lee","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0165","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/ajrccm\/146.5_Pt_1.1345","article-title":"Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment","volume":"146","author":"Xu","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/COPD.S27480","article-title":"Lung function decline in COPD","volume":"7","author":"Tantucci","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10545-006-0473-y","article-title":"Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment","volume":"30","author":"Heare","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejim.2013.05.003_bb0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1378\/chest.129.2.369","article-title":"Discriminating measures and normal values for expiratory obstruction","volume":"129","author":"Hansen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2013.05.003_bb0195","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1183\/09031936.93.02090817","article-title":"FEV1 decline in asymptomatic young adults: relationships with some tests of small airways function","volume":"2","author":"Marazzini","year":"1989","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0200","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1378\/chest.09-0800","article-title":"Bronchiolar disorders: a clinical-radiological diagnostic algorithm","volume":"137","author":"Devakonda","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2013.05.003_bb0205","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","article-title":"Standardisation of the single-breath determination of carbon monoxide uptake in the lung","volume":"26","author":"Macintyre","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2013.05.003_bb0210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0272-5231(05)70057-5","article-title":"Single-breath carbon monoxide diffusing capacity","volume":"22","author":"Crapo","year":"2001","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000226792","article-title":"Excessive daytime sleepiness is a common symptom in fabry disease","volume":"1","author":"Duning","year":"2009","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5664\/jcsm.26311","article-title":"Associations of sleep-disordered breathing and cerebral changes on MRI","volume":"1","author":"Robbins","year":"2005","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0230","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","article-title":"CNS manifestations of Fabry's disease","volume":"5","author":"Fellgiebel","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0235","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejim.2013.05.003_bb0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000331457","article-title":"Cheyne\u2013Stokes respiration in patients with heart failure: prevalence, causes, consequences and treatments","volume":"83","author":"Brack","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.ejim.2013.05.003_bb0245","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.humpath.2011.09.020","article-title":"Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study","volume":"43","author":"Chimenti","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejim.2013.05.003_bb0250","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1126\/science.169.3949.987","article-title":"Enzyme replacement in Fabry's disease, an inborn error of metabolism","volume":"169","author":"Mapes","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ejim.2013.05.003_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.05.003_bb0265","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2013.05.003_bb0270","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejim.2013.05.003_bb0280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol Genet Metab"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T01:25:55Z","timestamp":1688261155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0953620513001313"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.05.003","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary involvement in Fabry disease: Overview and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}